tgtx buyout rumors：Unusual Call Option Trade in TG Therapeutics (TGTX) ...
Unusual Call Option Trade in TG Therapeutics (TGTX) ...
2023年5月1日—UnusualCallOptionTradeinTGTherapeutics(TGTX)Worth$544.00K...OnMay1,2023at09:34:16ETanunusuallylarge$544.00KblockofCall ...。其他文章還包含有：「ExpectBiotechtoHeadHigherin2023」、「TGTherapeutics」、「TGTherapeutics」、「TGTherapeutics」、「TGTherapeutics」、「tgtxbuyout」、「TGTXNewsToday」、「TGTXStockBreaksOutOn'SolidJump'InMSDrugSales」、「TGTXStockLosesHalfItsValueOnB...
查看更多 離開網站
Expect Biotech to Head Higher in 2023
https://realmoney.thestreet.co
To recap, Thursday the FDA approved TG Therapeutics' (TGTX) Biologics License application for its compound ublituximab to treat certain adults ...
TG Therapeutics
https://finance.yahoo.com
Shares of TG Therapeutics (NASDAQ: TGTX) were crashing 50.4% lower as of 11:12 a.m. ET on Tuesday. Multiple sclerosis (MS) drug Briumvi, which launched in the ...
TG Therapeutics
https://finance.yahoo.com
Find the latest TG Therapeutics, Inc. (TGTX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and ...
TG Therapeutics
https://seekingalpha.com
TGTX withdrew its BLA/NDA for CLL due to OS complications. The stock may be hit hard on Monday.
TG Therapeutics
https://seekingalpha.com
After a year of churn and doldrums, TGTX finally got approval for, and launched, briumvi or ublituximab in RRMS. Read more here.
tgtx buyout
https://www.istock.tw
Get the latest TG Therapeutics Inc. (TGTX) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. People Also Ask.
TGTX News Today
https://www.marketbeat.com
TG Therapeutics (NASDAQ:TGTX) Stock Price Up 3.7% After Insider Buying Activity americanbankingnews.com - August 17 at 1:20 AM.
TGTX Stock Breaks Out On 'Solid Jump' In MS Drug Sales
https://www.investors.com
TG Therapeutics' new MS drug, Briumvi, experienced a solid jump in March sales, according to a report. TGTX stock broke out Tuesday.
TGTX Stock Loses Half Its Value On Briumvi Miss
https://www.investors.com
Sales of TG Therapeutics' (TGTX) highly anticipated multiple sclerosis drug, Briumvi, missed forecasts on Tuesday and TGTX stock plummeted.